Stop STALLING Act
Introduced Mar 24, 2025 by Sen. Amy Klobuchar
It's waiting on a committee vote to reach the full chamber. Most bills never leave this stage.
This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.
The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit is subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
Summary by the Congressional Research Service.
No floor votes yet — it hasn't reached the floor of either chamber.